Details of the Drug Combination

General Information of Drug Combination (ID: DCF9DDX)

Drug Combination Name
Sulindac Erlotinib
Indication
Disease Entry Status REF
Adenomatous Polyposis Coli Phase 1 [1]
Component Drugs Sulindac   DM2QHZU Erlotinib   DMCMBHA
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Sulindac
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [2]
Bursitis N.A. Approved [2]
Osteoarthritis FA00-FA05 Approved [2]
Rheumatoid arthritis FA20 Approved [3]
Colon cancer 2B90.Z Investigative [2]
Sulindac Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aldose reductase (AKR1B1) TTFBNVI ALDR_HUMAN Inhibitor [10]
------------------------------------------------------------------------------------
Sulindac Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [11]
------------------------------------------------------------------------------------
Sulindac Interacts with 201 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15) OT0RTR7M LOX15_HUMAN Increases Activity [12]
Arylamine N-acetyltransferase 1 (NAT1) OTCCNQ3H ARY1_HUMAN Decreases Expression [13]
Putative glutamine amidotransferase-like class 1 domain-containing protein 3B, mitochondrial (GATD3) OTBQRU82 GAL3B_HUMAN Decreases Expression [6]
Endosome/lysosome-associated apoptosis and autophagy regulator family member 2 (ELAPOR2) OTL628I1 ELAP2_HUMAN Increases Expression [6]
Protocadherin-17 (PCDH17) OTRK0M05 PCD17_HUMAN Decreases Expression [6]
Aurora kinase A (AURKA) OTMX0HYT AURKA_HUMAN Decreases Expression [6]
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (ATP2A1) OT959A3A AT2A1_HUMAN Decreases Expression [6]
NPC intracellular cholesterol transporter 1 (NPC1) OTRIPICX NPC1_HUMAN Increases Expression [6]
T-box transcription factor TBX3 (TBX3) OTM64N7K TBX3_HUMAN Increases Expression [6]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [6]
Monocarboxylate transporter 7 (SLC16A6) OT7BIIZX MOT7_HUMAN Increases Expression [6]
Origin recognition complex subunit 4 (ORC4) OT3ACTST ORC4_HUMAN Decreases Expression [6]
Bromodomain-containing protein 4 (BRD4) OT2Y2TCW BRD4_HUMAN Decreases Expression [6]
Transmembrane protein 127 (TMEM127) OTYHUXC1 TM127_HUMAN Increases Expression [6]
Hyaluronan mediated motility receptor (HMMR) OT4M0JTZ HMMR_HUMAN Decreases Expression [6]
Stanniocalcin-2 (STC2) OT86YP8G STC2_HUMAN Increases Expression [6]
Ribonuclease pancreatic (RNASE1) OTKZ7CO9 RNAS1_HUMAN Decreases Expression [6]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Increases Expression [6]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Increases Expression [6]
Calmodulin-1 (CALM2) OTNYA92F CALM1_HUMAN Decreases Expression [6]
Lysosomal acid phosphatase (ACP2) OTLPA1LJ PPAL_HUMAN Increases Expression [6]
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (MTHFD2) OT1LQSGX MTDC_HUMAN Increases Expression [6]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Decreases Expression [6]
Protein C-ets-1 (ETS1) OT4LVGDN ETS1_HUMAN Increases Expression [6]
Integrin alpha-2 (ITGA2) OTPFL017 ITA2_HUMAN Increases Expression [6]
Transcription factor JunD (JUND) OTNKACJD JUND_HUMAN Increases Expression [6]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Increases Expression [6]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [6]
Casein kinase II subunit alpha' (CSNK2A2) OT7MA2LV CSK22_HUMAN Increases Expression [6]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [6]
DNA excision repair protein ERCC-5 (ERCC5) OTQAKFJM ERCC5_HUMAN Decreases Expression [6]
High affinity cationic amino acid transporter 1 (SLC7A1) OTR2ZVA8 CTR1_HUMAN Increases Expression [6]
RAC-beta serine/threonine-protein kinase (AKT2) OTBB632K AKT2_HUMAN Decreases Expression [6]
Biotin--protein ligase (HLCS) OTPDUX30 BPL1_HUMAN Decreases Expression [6]
Plexin-A3 (PLXNA3) OTMZIBVG PLXA3_HUMAN Increases Expression [6]
Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 2 (NDST2) OT21PY3J NDST2_HUMAN Decreases Expression [6]
Small ubiquitin-related modifier 3 (SUMO3) OTTUJQJ1 SUMO3_HUMAN Decreases Expression [6]
Histone H4 (H4C1) OTB71W46 H4_HUMAN Increases Expression [6]
Casein kinase II subunit alpha (CSNK2A1) OT9T8WQM CSK21_HUMAN Decreases Expression [6]
Polycystin-1 (PKD1) OT5ALRZ5 PKD1_HUMAN Increases Expression [6]
Transcription initiation factor IIB (GTF2B) OTAH5NSO TF2B_HUMAN Increases Expression [6]
Cyclin-dependent kinase 3 (CDK3) OT2GP6RL CDK3_HUMAN Decreases Expression [6]
Cdc42 effector protein 1 (CDC42EP1) OTT525WA BORG5_HUMAN Increases Expression [6]
Growth factor receptor-bound protein 10 (GRB10) OTCKXGRC GRB10_HUMAN Increases Expression [6]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Increases Expression [6]
Krueppel-like factor 5 (KLF5) OT1ABI9N KLF5_HUMAN Increases Expression [6]
Dihydropyrimidinase (DPYS) OTLTUIVL DPYS_HUMAN Increases Expression [6]
Four and a half LIM domains protein 2 (FHL2) OT0OAYWT FHL2_HUMAN Increases Expression [6]
Endoplasmic reticulum membrane sensor NFE2L1 (NFE2L1) OT1QHOS2 NF2L1_HUMAN Increases Expression [6]
Kinesin-like protein KIF14 (KIF14) OTXHT4JM KIF14_HUMAN Increases Expression [6]
Syntaxin-binding protein 2 (STXBP2) OTX8GUC4 STXB2_HUMAN Increases Expression [6]
Nuclear factor interleukin-3-regulated protein (NFIL3) OTQH9HM3 NFIL3_HUMAN Increases Expression [6]
Phosphoenolpyruvate carboxykinase , mitochondrial (PCK2) OTJ8LX4N PCKGM_HUMAN Increases Expression [6]
TBC1 domain family member 10B (TBC1D10B) OT5MVCI5 TB10B_HUMAN Increases Expression [6]
Migration and invasion-inhibitory protein (MIIP) OT79EXZ7 MIIP_HUMAN Increases Expression [6]
Cyclin-J (CCNJ) OTCR4WVV CCNJ_HUMAN Decreases Expression [6]
OTU domain-containing protein 1 (OTUD1) OTE6O5XB OTUD1_HUMAN Increases Expression [6]
Tensin-3 (TNS3) OTPG2D8Z TENS3_HUMAN Decreases Expression [6]
F-box only protein 42 (FBXO42) OTHPN53C FBX42_HUMAN Increases Expression [6]
Metal transporter CNNM4 (CNNM4) OTUXJRM1 CNNM4_HUMAN Increases Expression [6]
Ankyrin repeat domain-containing protein 11 (ANKRD11) OTV0V70M ANR11_HUMAN Increases Expression [6]
La-related protein 4 (LARP4) OTB10IJH LARP4_HUMAN Increases Expression [6]
LIM domain-binding protein 1 (LDB1) OT20EAPR LDB1_HUMAN Increases Expression [6]
Transmembrane protein adipocyte-associated 1 (TPRA1) OTL61503 TPRA1_HUMAN Increases Expression [6]
Mitogen-activated protein kinase kinase kinase kinase 3 (MAP4K3) OTNJX38T M4K3_HUMAN Increases Expression [6]
UPF0690 protein C1orf52 (C1ORF52) OT8RQW3W CA052_HUMAN Increases Expression [6]
Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe (LFNG) OTPSUBN2 LFNG_HUMAN Increases Expression [6]
Osteoclast-stimulating factor 1 (OSTF1) OT8D7CDO OSTF1_HUMAN Increases Expression [6]
Caveolae-associated protein 3 (CAVIN3) OTOLBK79 CAVN3_HUMAN Increases Expression [6]
Sorting nexin-21 (SNX21) OT8O6909 SNX21_HUMAN Increases Expression [6]
Arrestin domain-containing protein 3 (ARRDC3) OTAKW7R9 ARRD3_HUMAN Increases Expression [6]
Splicing factor ESS-2 homolog (ESS2) OTZ08VCZ ESS2_HUMAN Increases Expression [6]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) OTAYZMOY SIR1_HUMAN Increases Expression [6]
Histone-lysine N-methyltransferase EHMT2 (EHMT2) OTC4DWB6 EHMT2_HUMAN Decreases Expression [6]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [6]
Sodium-coupled neutral amino acid symporter 2 (SLC38A2) OTALABSK S38A2_HUMAN Increases Expression [6]
Mediator of RNA polymerase II transcription subunit 15 (MED15) OT0D0JVD MED15_HUMAN Increases Expression [6]
Pleckstrin homology domain-containing family F member 1 (PLEKHF1) OT9OL16U PKHF1_HUMAN Increases Expression [6]
Sialidase-1 (NEU1) OTH9BY8Y NEUR1_HUMAN Increases Expression [6]
Translin-associated protein X (TSNAX) OTZ9SGWB TSNAX_HUMAN Decreases Expression [6]
Copine-1 (CPNE1) OTH5YKSL CPNE1_HUMAN Decreases Expression [6]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [6]
Allograft inflammatory factor 1-like (AIF1L) OTDEOB80 AIF1L_HUMAN Decreases Expression [6]
Ferroptosis suppressor protein 1 (AIFM2) OT57XWXO FSP1_HUMAN Increases Expression [6]
Transmembrane emp24 domain-containing protein 9 (TMED9) OTYGAQS0 TMED9_HUMAN Decreases Expression [6]
E3 ubiquitin-protein ligase RNF26 (RNF26) OTPXA60S RNF26_HUMAN Decreases Expression [6]
Tripartite motif-containing protein 2 (TRIM2) OT0V1YVC TRIM2_HUMAN Increases Expression [6]
Sorting nexin-25 (SNX25) OT8JY8M1 SNX25_HUMAN Increases Expression [6]
tRNA dimethylallyltransferase (TRIT1) OTCU9FS5 MOD5_HUMAN Decreases Expression [6]
PDZ and LIM domain protein 7 (PDLIM7) OTAZVODU PDLI7_HUMAN Increases Expression [6]
Phosphatidylinositol polyphosphate 5-phosphatase type IV (INPP5E) OTJF2AZ9 INP5E_HUMAN Increases Expression [6]
Transmembrane protein 39A (TMEM39A) OTRT51D9 TM39A_HUMAN Increases Expression [6]
Arginine and glutamate-rich protein 1 (ARGLU1) OTRVRZ4Z ARGL1_HUMAN Increases Expression [6]
SUN domain-containing protein 2 (SUN2) OT2IQJUC SUN2_HUMAN Decreases Expression [6]
B-cell receptor-associated protein 29 (BCAP29) OTLUBG86 BAP29_HUMAN Increases Expression [6]
Proton-coupled zinc antiporter SLC30A1 (SLC30A1) OTY8J0S4 ZNT1_HUMAN Increases Expression [6]
Solute carrier family 22 member 2 (SLC22A2) OTGFK1AL S22A2_HUMAN Decreases Activity [14]
Solute carrier family 22 member 1 (SLC22A1) OT7817I4 S22A1_HUMAN Decreases Activity [14]
Solute carrier family 22 member 6 (SLC22A6) OTKRCBVM S22A6_HUMAN Decreases Activity [14]
Organic anion transporter 7 (SLC22A9) OTO4BJCC S22A9_HUMAN Decreases Activity [14]
Solute carrier family 22 member 11 (SLC22A11) OTAJLNJZ S22AB_HUMAN Decreases Activity [14]
Solute carrier family 22 member 7 (SLC22A7) OTKTNH1W S22A7_HUMAN Decreases Activity [14]
Diamine acetyltransferase 1 (SAT1) OT52AU22 SAT1_HUMAN Increases Expression [15]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [16]
Sulfotransferase 1E1 (SULT1E1) OTGPJ517 ST1E1_HUMAN Decreases Activity [17]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Expression [7]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Increases Expression [7]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Increases Localization [7]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Increases Expression [7]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Decreases Activity [18]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Decreases Activity [18]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Decreases Activity [18]
Ladinin-1 (LAD1) OT6YGTVX LAD1_HUMAN Increases Expression [19]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [20]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB) OT9RDS3H IKKB_HUMAN Decreases Activity [21]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Increases Expression [22]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Increases Expression [23]
Serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1) OTY9R6FZ ERN1_HUMAN Increases Expression [24]
DNA fragmentation factor subunit beta (DFFB) OTPBW5N5 DFFB_HUMAN Affects Localization [25]
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Affects Localization [25]
Renin (REN) OT52GZR2 RENI_HUMAN Decreases Activity [26]
Metalloproteinase inhibitor 1 (TIMP1) OTOXC51H TIMP1_HUMAN Affects Expression [27]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Increases Expression [28]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Increases Expression [29]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [30]
HLA class I histocompatibility antigen, B alpha chain (HLA-B) OTNXFWY2 HLAB_HUMAN Affects Expression [31]
Apolipoprotein C-III (APOC3) OTW3520C APOC3_HUMAN Decreases Secretion [24]
Ferritin heavy chain (FTH1) OT6IFS0O FRIH_HUMAN Increases Expression [8]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Decreases Secretion [24]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [32]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Decreases Expression [33]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [34]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Expression [35]
Protein disulfide-isomerase (P4HB) OTTYNYPF PDIA1_HUMAN Decreases Expression [24]
Decorin (DCN) OTWLJL7K PGS2_HUMAN Decreases Expression [19]
Proto-oncogene tyrosine-protein kinase receptor Ret (RET) OTLU040A RET_HUMAN Affects Expression [27]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Decreases Expression [36]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Activity [32]
Clusterin (CLU) OTQGG0JM CLUS_HUMAN Affects Expression [27]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [37]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Increases Expression [8]
Transcription factor 4 (TCF4) OTB9ASTK ITF2_HUMAN Decreases Activity [38]
Neuromodulin (GAP43) OT2OTGGV NEUM_HUMAN Affects Expression [27]
Cyclic AMP-dependent transcription factor ATF-6 alpha (ATF6) OTAFHAVI ATF6A_HUMAN Increases Expression [24]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Decreases Activity [39]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [34]
Galanin peptides (GAL) OTB3VPTO GALA_HUMAN Affects Expression [27]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [40]
G1/S-specific cyclin-E1 (CCNE1) OTLD7UID CCNE1_HUMAN Decreases Expression [34]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Activity [41]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Decreases Phosphorylation [42]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [36]
Protein-lysine 6-oxidase (LOX) OT1C2HIU LYOX_HUMAN Decreases Expression [43]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [36]
Protein PML (PML) OT6SM2GD PML_HUMAN Increases Expression [35]
Leukocyte elastase inhibitor (SERPINB1) OT5RDUFO ILEU_HUMAN Increases Expression [19]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [43]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Increases Expression [23]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Decreases Expression [44]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [40]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [45]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Decreases Expression [35]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [19]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Expression [46]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [47]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Increases Expression [23]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Increases Expression [24]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Decreases Phosphorylation [38]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Response To Substance [48]
ATP-citrate synthase (ACLY) OTRL9ZRP ACLY_HUMAN Increases Expression [24]
Microsomal triglyceride transfer protein large subunit (MTTP) OTNUVSDT MTP_HUMAN Increases Expression [24]
Nucleosome assembly protein 1-like 1 (NAP1L1) OTI7WBZV NP1L1_HUMAN Decreases Expression [19]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [32]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Decreases Expression [34]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Increases Activity [30]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Decreases Expression [34]
Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase (GCNT1) OTF6OC66 GCNT1_HUMAN Increases Expression [8]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Affects Activity [49]
Peroxisome proliferator-activated receptor delta (PPARD) OTI4WTOP PPARD_HUMAN Increases Expression [50]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Increases Expression [35]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [51]
Interleukin-24 (IL24) OT4VUWH1 IL24_HUMAN Increases Expression [32]
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Increases Expression [24]
Integrin-linked protein kinase (ILK) OTYG2FD1 ILK_HUMAN Decreases Activity [38]
Endonuclease G, mitochondrial (ENDOG) OT5IM7B3 NUCG_HUMAN Affects Localization [25]
Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein (HERPUD1) OT9EROL6 HERP1_HUMAN Increases Expression [8]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Affects Localization [52]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Decreases Expression [43]
Carbonic anhydrase 9 (CA9) OTNA51XT CAH9_HUMAN Decreases Expression [43]
Dehydrogenase/reductase SDR family member 11 (DHRS11) OTU3J0ZL DHR11_HUMAN Decreases Activity [53]
Protein NDRG1 (NDRG1) OTVO66BO NDRG1_HUMAN Increases Expression [35]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Decreases Expression [54]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Decreases Expression [22]
Transmembrane 7 superfamily member 3 (TM7SF3) OTT9RKL6 TM7S3_HUMAN Decreases Expression [8]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Increases Expression [24]
Serine/threonine-protein kinase TBK1 (TBK1) OT1P06NV TBK1_HUMAN Increases Expression [8]
Angiopoietin-related protein 3 (ANGPTL3) OTCD5Z9W ANGL3_HUMAN Decreases Expression [24]
eIF5-mimic protein 1 (BZW2) OTBT0A1B 5MP1_HUMAN Decreases Expression [8]
Flavin-containing monooxygenase 3 (FMO3) OT1G2EV3 FMO3_HUMAN Increases Metabolism [55]
GTPase KRas (KRAS) OT78QCN8 RASK_HUMAN Affects Response To Substance [56]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Response To Substance [51]
------------------------------------------------------------------------------------
⏷ Show the Full List of 201 DOT(s)
Indication(s) of Erlotinib
Disease Entry ICD 11 Status REF
Adrenal gland neoplasm N.A. Approved [4]
Adult hepatocellular carcinoma N.A. Approved [4]
Brain cancer 2A00 Approved [4]
Esophageal disorder N.A. Approved [4]
Lung cancer 2C25.0 Approved [4]
Non-small-cell lung cancer 2C25.Y Approved [5]
Pancreatic adenocarcinoma N.A. Approved [4]
Psoriasis EA90 Approved [4]
Salivary gland squamous cell carcinoma N.A. Approved [4]
Pancreatic cancer 2C10 Phase 3 [5]
Colon cancer 2B90.Z Phase 2 [5]
Ependymoma 2A00.0Y Investigative [4]
Neoplastic meningitis N.A. Investigative [4]
Neuroblastoma 2D11.2 Investigative [4]
Erlotinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [57]
------------------------------------------------------------------------------------
Erlotinib Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [58]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [59]
------------------------------------------------------------------------------------
Erlotinib Interacts with 4 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [60]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [61]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [61]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [61]
------------------------------------------------------------------------------------
Erlotinib Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Increases Response [62]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Squamous Cell Carcinoma of the Head and Neck (SCCHN) DC4Q7LG N. A. Phase 1 [63]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01187901) A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
2 Sulindac FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5425).
4 Erlotinib FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
6 Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
7 Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2008 Mar 1;122(5):990-8.
8 Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer. 2000 Dec 15;88(6):873-80. doi: 10.1002/1097-0215(20001215)88:6<873::aid-ijc6>3.0.co;2-b.
9 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
10 Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
11 Fluo-cAMP is transported by multidrug resistance-associated protein isoform 4 in rat choroid plexus. J Neurochem. 2010 Oct;115(1):200-8.
12 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst. 2000 Jul 19;92(14):1136-42.
13 Sulindac inhibited gene expression and activity of arylamine N-acetyltransferase and DNA-2-aminofluorene adduct formation in T24 human bladder tumor cells. Urol Res. 2001 Dec;29(6):406-11.
14 Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
15 Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem. 2003 Nov 28;278(48):47762-75.
16 Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac. World J Gastroenterol. 2005 Mar 28;11(12):1829-32.
17 Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
18 Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
19 p21(WAF1/cip1) is an important determinant of intestinal cell response to sulindac in vitro and in vivo. Cancer Res. 2001 Aug 15;61(16):6297-302.
20 Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80. doi: 10.1093/jnci/djh322.
21 Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKbeta. Apoptosis. 2009 Jul;14(7):913-22. doi: 10.1007/s10495-009-0367-1.
22 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
23 Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1427-33. doi: 10.1006/bbrc.2002.6367.
24 Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
25 Sulindac activates nuclear translocation of AIF, DFF40 and endonuclease G but not induces oligonucleosomal DNA fragmentation in HT-29 cells. Life Sci. 2005 Sep 2;77(16):2059-70. doi: 10.1016/j.lfs.2005.04.021.
26 Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med. 1990 Sep;89(3):313-21. doi: 10.1016/0002-9343(90)90344-d.
27 Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays. Physiol Genomics. 2002 Oct 29;11(2):45-52. doi: 10.1152/physiolgenomics.00064.2002.
28 Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res. 2002 Nov 1;62(21):6006-10.
29 Enhanced apoptosis and transforming growth factor-beta1 expression in colorectal adenomas and carcinomas after Sulindac therapy. Dis Colon Rectum. 2001 Jul;44(7):1008-15. doi: 10.1007/BF02235490.
30 Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine. 1999 May;11(5):347-58. doi: 10.1006/cyto.1998.0437.
31 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
32 Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
33 The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB. Oncogene. 2008 Apr 17;27(18):2648-55. doi: 10.1038/sj.onc.1210891. Epub 2007 Dec 3.
34 Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
35 Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
36 Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol Rep. 2008 Aug;20(2):379-84.
37 JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo. Eur J Pharmacol. 2007 Apr 10;560(2-3):95-100. doi: 10.1016/j.ejphar.2007.01.020. Epub 2007 Jan 19.
38 Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene. 2001 Sep 27;20(43):6250-7. doi: 10.1038/sj.onc.1204791.
39 The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res. 2008 Oct 15;68(20):8269-77. doi: 10.1158/0008-5472.CAN-08-2010.
40 Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
41 Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest. Int J Cancer. 2003 Dec 10;107(5):844-53. doi: 10.1002/ijc.11446.
42 Protein phosphatase 2A interacts with and directly dephosphorylates RelA. J Biol Chem. 2001 Dec 21;276(51):47828-33. doi: 10.1074/jbc.M106103200. Epub 2001 Oct 8.
43 NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int J Cancer. 2009 Jan 1;124(1):223-32. doi: 10.1002/ijc.23934.
44 Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008 Mar 31;583(1):26-31. doi: 10.1016/j.ejphar.2007.12.034. Epub 2008 Feb 5.
45 Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury. Toxicol Sci. 2014 Jan;137(1):234-48. doi: 10.1093/toxsci/kft232. Epub 2013 Oct 17.
46 Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma. Neoplasia. 2007 Mar;9(3):192-9. doi: 10.1593/neo.06781.
47 Sulindac induces apoptosis, inhibits proliferation and activates caspase-3 in Hep G2 cells. Anticancer Res. 2002 Jan-Feb;22(1A):263-6.
48 TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells. J Pathol. 2011 Feb;223(3):378-89. doi: 10.1002/path.2797. Epub 2010 Oct 29.
49 Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
50 Functional characterization of peroxisome proliferator-activated receptor-/ expression in colon cancer. Mol Carcinog. 2011 Nov;50(11):884-900. doi: 10.1002/mc.20757. Epub 2011 Mar 11.
51 Role of BAX in the apoptotic response to anticancer agents. Science. 2000 Nov 3;290(5493):989-92. doi: 10.1126/science.290.5493.989.
52 Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction. Apoptosis. 2007 Jan;12(1):195-209. doi: 10.1007/s10495-006-0527-5.
53 Rabbit dehydrogenase/reductase SDR family member 11 (DHRS11): Its identity with acetohexamide reductase with broad substrate specificity and inhibitor sensitivity, different from human DHRS11. Chem Biol Interact. 2019 May 25;305:12-20. doi: 10.1016/j.cbi.2019.03.026. Epub 2019 Mar 26.
54 Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells. Cancer Res. 2003 Feb 1;63(3):616-20.
55 Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin Cancer Res. 2004 Dec 15;10(24):8357-62. doi: 10.1158/1078-0432.CCR-04-1073.
56 Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis. Clin Cancer Res. 2001 Dec;7(12):4000-7.
57 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
58 Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008 Aug;7(8):2280-7.
59 Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33.
60 In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
61 Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
62 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
63 ClinicalTrials.gov (NCT00392665) Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck